Pompe Disease Clinical Trial
Official title:
An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naïve and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients.
Verified date | March 2023 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objective: To evaluate the safety and tolerability of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. Secondary Objective: To evaluate the pharmacokinetics, pharmacodynamics of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. To evaluate the effect of neoGAA on exploratory efficacy endpoints in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients.
Status | Completed |
Enrollment | 24 |
Est. completion date | February 25, 2015 |
Est. primary completion date | February 25, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria : For both Group 1 and Group 2: - Male or female patients with confirmed acid a-glucosidase (GAA) enzyme deficiency from any tissue source and/or confirmed GAA gene mutation and without known cardiac hypertrophy. - Patient willing and able to provide signed informed consent - Patient is able to ambulate 50 meters (approximately 160 feet) without stopping and without an assistive device. Use of assistive device for community ambulation is appropriate. - Patient has a forced vital capacity (FVC) in upright position of =50% predicted. - The patient, if female and of childbearing potential, must have a negative pregnancy test [urine beta-human chorionic gonadotropin (ß-hCG)] at baseline. Group 2 patients only: - The patient has been previously treated with alglucosidase alfa for at least 9 months. Exclusion criteria: For both Group 1 and Group 2: - Patient is wheelchair dependent. - Patient requires invasive-ventilation (non-invasive ventilation is allowed). - Patient is participating in another clinical study using investigational treatment. - Patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study. - Patient has clinically significant organic disease (with the exception of symptoms relating to Pompe disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, precludes participation in the study or potentially decreases survival. - Patient cannot submit to MRI examination because of a formal contraindication such as a pacemaker, implanted ferromagnetic metals, anxiety disorder, etc. Group 1 only: - Patient has had previous treatment with alglucosidase alfa or any other enzyme replacement therapy (ERT) for Pompe disease. Group 2 only: - Patient has a high risk for a severe allergic reaction to neoGAA (i.e. previous moderate to severe anaphylactic reaction to alglucosidase alfa and/or patient has immunoglobulin (Ig) E antibodies to alglucosidase alfa, and/or a history of sustained high immunoglobulin G (IgG) antibody titers to alglucosidase alfa that in the opinion of the investigator suggest a high risk for an allergic reaction to neoGAA). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
Belgium | Investigational Site Number 056001 | Leuven | |
Denmark | Investigational Site Number 208001 | København Ø | |
France | Investigational Site Number 250001 | Marseille | |
France | Investigational Site Number 250003 | Nice | |
France | Investigational Site Number 250002 | Paris | |
Germany | Investigational Site Number 276003 | Mainz | |
Germany | Investigational Site Number 276001 | München | |
Germany | Investigational Site Number 276002 | Münster | |
Netherlands | Investigational Site Number 528001 | Rotterdam | |
United Kingdom | Investigational Site Number 826003 | Newcastle Upon Tyne | |
United States | Investigational Site Number 840009 | Dallas | Texas |
United States | Investigational Site Number 840002 | Durham | North Carolina |
United States | Investigational Site Number 840003 | Fairfax | Virginia |
United States | Investigational Site Number 840010 | Jacksonville | Florida |
United States | Investigational Site Number 840001 | Kansas City | Kansas |
United States | Investigational Site Number 840006 | Phoenix | Arizona |
United States | Investigational Site Number 840008 | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events | screening/baseline to Week 25 | ||
Primary | Laboratory assessments including hematology, biochemistry and urinalysis | screening/baseline to Week 25 | ||
Primary | Vital signs | screening/baseline to Week 25 | ||
Secondary | Electrocardiogram | screening/baseline, Week 1, Week 13, Week 25 | ||
Secondary | Immunogenicity assessments | screening/baseline to Week 29 | ||
Secondary | Cmax | Week 1, Week 13, Week 25 | ||
Secondary | AUC | Week 1, Week 13, Week 25 | ||
Secondary | t1/2 | Week 1, Week 13, Week 25 | ||
Secondary | Skeletal muscle glycogen content | screening/baseline, Week 27 | ||
Secondary | Skeletal muscle magnetic resonance images for qualitative and quantitative muscle degenerative assessments. | screening/baseline, Week 27 | ||
Secondary | Urinary Hex4 | screening/baseline to Week 25 | ||
Secondary | Functional assessments including 6 Minute Walk Test (6MWT) | Functional Assessment includes - pulmonary function testing (PFT) endpoints, Gait, Stair, Gower's Maneuver, Chair (GSGC), Gross Motor Function Measure-88 (GMFM-88), Quick Motor Function Test (QMFT), hand-held dynamometer testing, Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL) | screening/baseline, Week 13, Week 25 | |
Secondary | Quality of life assessments | screening/baseline, Week 13, Week 25 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01942590 -
Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01409486 -
Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry
|
N/A | |
Completed |
NCT00976352 -
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT01665326 -
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
|
||
Completed |
NCT01758354 -
Newborn Screening Assay of Pompe's Disease
|
N/A | |
Recruiting |
NCT00231400 -
Pompe Disease Registry Protocol
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT04476550 -
Clinical Specimen Collection From Pompe Disease Patients
|
||
Completed |
NCT01380743 -
Drug-drug Interaction Study
|
Phase 2 | |
Recruiting |
NCT05734521 -
Avalglucosidase Alfa Pregnancy Study
|
||
Completed |
NCT02742298 -
Pompe Disease QMUS and EIM
|
N/A | |
Terminated |
NCT02185651 -
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
|
Phase 1 | |
Completed |
NCT02654886 -
Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
|
N/A | |
Completed |
NCT02405598 -
Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
|
Phase 4 | |
Completed |
NCT00701129 -
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
|
Phase 4 | |
Completed |
NCT01451879 -
Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
|
N/A | |
Completed |
NCT02240407 -
Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease
|
Phase 1 | |
Completed |
NCT05073783 -
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
|
||
Active, not recruiting |
NCT04093349 -
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
|
Phase 1/Phase 2 | |
Completed |
NCT02363153 -
Diet and Exercise in Pompe Disease
|
N/A |